BREAKING
Home » Posts Tagged "Brilacidin"

Brilacidin granted QIDP designation to treat skin infections

By

Biopharmaceutical company, Cellceutix Corporation announced today that the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) designation for Brilacidin as...

Single-Dose Brilacidin Comparable to 7-Days of Daptomycin in treating skin infections

By

Cellceutix Corporation, a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology and antibiotic applications, is pleased to announce positive top-line results...

Cellceutix completes enrollment in its Phase 2b trial comparing Brilacidin to daptomycin

By

Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, has announced the completion of enrollment in...

Novel MRSA antibiotic, Brilacidin, receives positive review in Phase IIb safety study

By

Cellceutix announced another important milestone in the development of Brilacidin™, the lead compound in a novel class of antibiotics known as defensin-mimetics.   In the Company’s phase 2b study...